Apparent partial loss of CD123 expression in blastic plasmacytoid dendritic cell neoplasm after treatment with CD123-targeted therapy: A novel finding and possible diagnostic pitfall

J Dermatol. 2020 Oct;47(10):e354-e355. doi: 10.1111/1346-8138.15456. Epub 2020 Aug 7.

Authors

Phyu P Aung¹, Naveen Pemmaraju², Carlos A Torres-Cabala^{1

3}, Madeleine Duvic³, Marina Konopleva², Joseph D Khoury⁴, Victor G Prieto^{1

3}

Affiliations

¹ Departments of, Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
² Departments of, Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
³ Departments of, Dermatology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
⁴ Departments of, Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

PMID: 32770556
DOI: 10.1111/1346-8138.15456

No abstract available

Publication types

Letter

MeSH terms

Dendritic Cells
Hematologic Neoplasms* / diagnosis
Hematologic Neoplasms* / drug therapy
Humans
Interleukin-3 Receptor alpha Subunit
Skin Neoplasms* / diagnosis
Skin Neoplasms* / drug therapy

Substances

Interleukin-3 Receptor alpha Subunit